公开(公告)号：US20240182567A1

公开(公告)日：2024-06-06

申请号：US18583551

申请日：2024-02-21

申请人： National University of Singapore

发明人： Yi Tian Png ,  Natasha Vinanica ,  Takahiro Kamiya ,  Dario Campana

IPC分类号： C07K16/28 ,  A61K35/17 ,  A61K38/00 ,  A61K39/00 ,  A61P35/02 ,  C07K14/705 ,  C07K14/725 ,  C07K16/30

CPC分类号： C07K16/2803 ,  A61K35/17 ,  A61K39/001129 ,  A61P35/02 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/3061 ,  A61K38/00 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/804 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/04 ,  C07K2319/05 ,  C07K2319/33 ,  C07K2319/74

摘要： The present invention provides compositions comprising an anti-CD7 chimeric activating receptor (CAR) and an anti-CD7 protein expression blocker, and methods of using such compositions in cancer therapy.

公开(公告)号：US20190248915A1

公开(公告)日：2019-08-15

申请号：US16272350

申请日：2019-02-11

申请人： Forty Seven, Inc.

发明人： Mark Ping Chao ,  Chris Hidemi Mizufune Takimoto ,  Jens-Peter Volkmer

IPC分类号： C07K16/30 ,  C07K16/28 ,  A61P35/00

CPC分类号： C07K16/30 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/55 ,  A61K2039/804 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/732

摘要： Methods, kits, and compositions are provided herein that can be used to treat CD20+cancer using an anti-CD47 agent such as an antibody. The anti-CD47 agent can be used alone or in combination with one or more additional agent such as an anti-CD20 antibody.

公开(公告)号：US20180169207A1

公开(公告)日：2018-06-21

申请号：US15836943

申请日：2017-12-11

申请人： Andrei Valentinovich IVLEV

发明人： Vladislav Nikolaevich LASKAVY

IPC分类号： A61K39/04 ,  C07K14/35 ,  A61K9/00 ,  A61P35/02

CPC分类号： A61K39/04 ,  A61K9/0019 ,  A61K2039/552 ,  A61K2039/585 ,  A61K2039/804 ,  A61P35/02 ,  C07K14/35

摘要： The invention generally relates to the field of veterinary medicine and can be used for bovine leukemia prevention. The invention expands the range of means of the claimed application and provides lifelong resistance of animals to the leukemia virus.The invention is aimed at solving the problem of expanding the range of preventive medications and forming new approaches to the problem of preventing bovine leukemia, which allow ensuring lifelong resistance of the animals to leukemia infection.The technical result consists in the design of a remedy and use thereof for bovine leukemia prevention, which would allow providing a targeted immune response, efficiently and with minimal costs, by activating cellular immunity against bovine leukemia virus by increasing the number of killer cells.The remedy for bovine leukemia prevention contains a water-soluble protein fraction with a molecular weight of 18-20 kDa, isolated from the tuberculosis mycobacterium destruction products, characterized by the presence of peaks at a wavelength of 214 nm in the UV region, a phosphate-buffered saline, an aqueous formaldehyde solution, and an isotonic sodium chloride solution.The use consists in administering the said remedy to 1 to 9 days old calves with a single intramuscular injection at a dose of 4.0-6.0 ml per capita.

公开(公告)号：US20240327921A1

公开(公告)日：2024-10-03

申请号：US18129791

申请日：2023-03-31

申请人： Cameron Kamran Tebbi

发明人： Cameron Kamran Tebbi

IPC分类号： C12Q1/6886 ,  A61K39/00

CPC分类号： C12Q1/6886 ,  A61K39/0002 ,  A61K2039/585 ,  A61K2039/804 ,  C12Q2600/156

摘要： A method for detection and prevention of leukemia and lymphoma is disclosed. When mononuclear blood cells from an individual are exposed to a supernatant of a mycovirus-containing Aspergillus flavus, the degree and pattern of activation and upregulation or downregulation transcription factors are indicative of an individual's susceptibility to leukemia or lymphoma. Upon detection of observed transcription factors, preventive measures are provided to the individual. Preventive measures may include, for example, a vaccine, or may be provided upon detection of observed transcription factors with those individuals that are genetically susceptible to leukemia and lymphoma.

公开(公告)号：US20240189406A1

公开(公告)日：2024-06-13

申请号：US18528327

申请日：2023-12-04

申请人： SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

发明人： Yeonseok CHUNG ,  Suyoung LEE ,  Da-Sol KUEN ,  Byung-Soo KIM ,  Jihye HONG ,  Byung-Sik CHO

IPC分类号： A61K39/00 ,  A61K45/06 ,  A61P35/02

CPC分类号： A61K39/001129 ,  A61K45/06 ,  A61P35/02 ,  A61K2039/55555 ,  A61K2039/804

摘要： The present invention provides a natural killer T cell ligand-loaded extracellular nanovesicle, and an autologous anticancer vaccine for hematologic malignancies including the above extracellular nanovesicle. More particularly, a cancer cell-derived extracellular nanovesicle in which a natural killer T cell ligand as an adjuvant is bound to a surface thereof, and an autologous anticancer vaccine including the same, which can recognize cancer antigens specific to patients with hematologic malignancies and has cancer cell-specific anticancer function thus to enable T cell activation.

公开(公告)号：US11945865B2

公开(公告)日：2024-04-02

申请号：US17865292

申请日：2022-07-14

申请人： National University of Singapore

发明人： Yi Tian Png ,  Natasha Vinanica ,  Takahiro Kamiya ,  Dario Campana

IPC分类号： A61K38/00 ,  A61K35/17 ,  A61K39/00 ,  A61P35/02 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30

CPC分类号： C07K16/2803 ,  A61K35/17 ,  A61K39/001129 ,  A61P35/02 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/3061 ,  A61K38/00 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/804 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/04 ,  C07K2319/05 ,  C07K2319/33 ,  C07K2319/74

摘要： The present invention provides compositions comprising an anti-CD7 chimeric activating receptor (CAR) and an anti-CD7 protein expression blocker, and methods of using such compositions in cancer therapy.

公开(公告)号：US20190192567A1

公开(公告)日：2019-06-27

申请号：US16212198

申请日：2018-12-06

申请人： Immatics Biotechnologies GmbH

发明人： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/00

CPC分类号： A61K35/17 ,  A61K39/0011 ,  A61K39/001102 ,  A61K39/00114 ,  A61K2039/5158 ,  A61K2039/572 ,  A61K2039/585 ,  A61K2039/804 ,  A61K2039/844 ,  A61K2039/86 ,  A61K2039/884 ,  A61P35/00

摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20180201661A1

公开(公告)日：2018-07-19

申请号：US15885301

申请日：2018-01-31

申请人： Onkimmune Limited

发明人： Michael Eamon Peter O'DWYER

IPC分类号： C07K14/52 ,  A61K35/17 ,  A61K38/19 ,  C12N5/0783 ,  A61P35/00 ,  A61P35/02 ,  A61K31/69 ,  A61K39/00

CPC分类号： C07K14/52 ,  A61K31/69 ,  A61K35/17 ,  A61K38/19 ,  A61K39/0011 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/572 ,  A61K2039/804 ,  A61P35/00 ,  A61P35/02 ,  C12N5/0646 ,  C12N2510/00

摘要： NK cells and NK cell lines are modified to increase cytotoxicity, wherein the cells and compositions thereof have a use in the treatment of cancer. Production of modified NK cells and NK cell lines is via genetic modification to add mutant (variant) TRAIL ligand expression.

公开(公告)号：US12091717B1

公开(公告)日：2024-09-17

申请号：US18129791

申请日：2023-03-31

申请人： Cameron Kamran Tebbi

发明人： Cameron Kamran Tebbi

IPC分类号： C12Q1/6886 ,  A61K39/00

CPC分类号： C12Q1/6886 ,  A61K39/0002 ,  A61K2039/585 ,  A61K2039/804 ,  C12Q2600/156

摘要： A method for detection and prevention of leukemia and lymphoma is disclosed. When mononuclear blood cells from an individual are exposed to a supernatant of a mycovirus-containing Aspergillus flavus, the degree and pattern of activation and upregulation or downregulation transcription factors are indicative of an individual's susceptibility to leukemia or lymphoma. Upon detection of observed transcription factors, preventive measures are provided to the individual. Preventive measures may include, for example, a vaccine, or may be provided upon detection of observed transcription factors with those individuals that are genetically susceptible to leukemia and lymphoma.

公开(公告)号：US20240269252A1

公开(公告)日：2024-08-15

申请号：US18544197

申请日：2023-12-18

申请人： President and Fellows of Harvard College ,  The General Hospital Corporation

发明人： Nisarg J. Shah ,  Ting-Yu Shih ,  Angelo S. Mao ,  David J. Mooney ,  David T. Scadden

IPC分类号： A61K39/00 ,  A61K31/704 ,  A61K31/7068 ,  A61K39/39

CPC分类号： A61K39/001153 ,  A61K39/39 ,  A61K31/704 ,  A61K31/7068 ,  A61K2039/545 ,  A61K2039/55561 ,  A61K2039/572 ,  A61K2039/6087 ,  A61K2039/6093 ,  A61K2039/804

摘要： Acute myeloid leukemia (AML) is a clonal disorder of hematopoietic stem and progenitor cells. It is a devastating disease with a poor prognosis and an average 5-year survival rate of about 30%. Disclosed herein are composition and methods for treating leukemia with a biomaterial comprising a polymer scaffold, a dendritic cell activating factor, a dendritic cell recruitment factor, and at least one leukemia antigen. The biomaterial-based vaccine disclosed herein promotes a potent, durable and transferable immune response against acute myeloid leukemia to prevent cell engraftment and synergizes with chemotherapy to prevent relapse.